Form 4: Teva Pharmaceutical Industries Executive Receives Restricted Share Units
SEC Form 4 Filing
Christine Fox, EVP, Head of U.S. Commercial at Teva Pharmaceutical Industries, was granted 71,278 restricted share units on March 5, 2025, according to a Form 4 filing.
Summary
- Christine Fox, an executive at Teva Pharmaceutical Industries, received 71,278 restricted share units on March 5, 2025.
- These units will vest in installments over four years, starting March 5, 2026.
- Each restricted share unit represents the right to receive one ordinary share or its cash value.
- The filing was submitted to the SEC on March 7, 2025.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral to slightly positive event.
Positives
- The grant of restricted share units aligns the executive's interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the executive.
Future Outlook
The vesting of the restricted share units over the next four years suggests an expectation of continued service and contribution from the executive.
Industry Context
Granting restricted share units is a common practice in the pharmaceutical industry to incentivize and retain key executives.
Comparison to Industry Standards
- Executive compensation packages in the pharmaceutical industry often include a mix of salary, bonus, and equity-based awards like restricted share units.
- Companies such as Pfizer, Novartis, and Johnson & Johnson also utilize similar equity-based compensation strategies to align executive interests with shareholder value.
- The vesting schedule of these units is fairly standard, with multi-year vesting periods being common to encourage long-term commitment.
Stakeholder Impact
- Shareholders may view the grant of restricted share units as a positive sign, aligning executive interests with long-term company performance.
- Employees may see this as a sign of stability and investment in leadership.
Key Dates
| Date | Description |
|---|---|
| 03/05/2025 | Date of earliest transaction: Grant date of restricted share units. |
| 03/05/2026 | First vesting date: 17,819 restricted share units vest. |
| 03/05/2027 | Second vesting date: 17,819 restricted share units vest. |
| 03/05/2028 | Third vesting date: 17,819 restricted share units vest. |
| 03/05/2029 | Fourth vesting date: 17,821 restricted share units vest. |
| 03/07/2025 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.